Noteworthy Ariad receives core patent on signal transduction technology

Ariad Pharmaceuticals Inc. was the announce today that it has received its first patent, covering its core programs in a broad area of drug discovery involving intracellular signal transduction.

U.S. Patent No. 5,352,660, a method for assaying a substance that affects an SH2-phosphorylated ligand regulatory system, was issued to Mount Sinal Hospital Corp. of Toronto. ARIA is the exclusive worldwide licensee to all applications of